Active ingredients: panitumumab
What it is used for
Vectibix is indicated for the treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC) (see PRECAUTIONS Laboratory tests): - as first line therapy in combination with FOLFOX. Efficacy may be influenced by patient performance status (see CLINICAL TRIALS; PRECAUTIONS). - as second line therapy in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). Efficacy may be influenced by patient performance status (see CLINICAL TRIALS). - as monotherapy in patients after the failure of standard chemotherapy.
How to take it
The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Colourless liquid; may contain translucent to white amorphous proteinaceous particles.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient panitumumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems